

## DAFTAR PUSTAKA

- Albayrak, Y. dan Kuloglu, M. (2013) 'A Catatonic Schizophrenia Case Treated Effectively with Aripiprazole', *Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology*, 23(3), pp. 257–260. doi: 10.5455/bcp.20130127022449.
- Alexxander, A. and Pratiwi, R. D. (2024b) 'Evaluasi Tepat Pasien, Tepat Obat Dan Tepat Dosis Antipsikotik Pasien Rawat Inap Skizofrenia Paranoid di RSJ Sambang Lihum', *Jurnal Insan Farmasi Indonesia*, 7(2), pp. 1–12. doi: 10.36387/jifi.v7i2.2140.
- Ali, T. dkk. (2021) 'Antipsychotic-induced extrapyramidal side effects: A systematic review and meta-analysis of observational studies', *PLOS ONE*, 16(9), p. e0257129. doi: 10.1371/journal.pone.0257129.
- Allredge, B. K. ., Koda-Kimble, M. Anne. dan Young, L. Y. . (2013) *Applied therapeutics : the clinical use of drugs*. 10th edn. Wolters Kluwer/Lippincott Williams & Wilkins.
- Als fouk, B. A., Aljanadi, Q. M. dan Almutairi, M. M. (2025) 'Evaluation of drug interactions in outpatients taking antipsychotic medications', *Frontiers in Pharmacology*, 16. doi: 10.3389/fphar.2025.1590167.
- American Psychiatric Association (APA) (2013) 'Schizophrenia spectrum and other psychotic disorders', in *Diagnostic and Statistical Manual of Mental Disorders (DSM-5)*. 5th edn. Arlington, VA: American Psychiatric Association, pp. 87–122.
- American Psychiatric Association (APA) (2021) *The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia*. American Psychiatric Association.
- Anggraeni, M. D. (2024) *Hubungan antara Kejadian Drug Related Problems dan Outcome Klinis pada Pasien Depresi*. Universitas Gadjah Mada.
- Ayano, G. (2016) 'Schizophrenia: A Concise Overview of Etiology, Epidemiology Diagnosis and Management: Review of literatures', *J Schizophr Res*, 3(2). Available at: [www.austinpublishinggroup.com](http://www.austinpublishinggroup.com).
- Baandrup, L. (2020) 'Polypharmacy in schizophrenia', *Basic & Clinical Pharmacology & Toxicology*, 126(3), pp. 183–192. doi: 10.1111/bcpt.13384.
- Badan Pengawas Obat dan Makanan and Japan International Cooperation Agency (2020) *Modul Farmakovigilans untuk Tenaga Profesional Kesehatan: Proyek "Ensuring drug and food safety"*. Jakarta: BPOM dan JICA.
- Baker, R. W. dkk. (2003) 'Effectiveness of Rapid Initial Dose Escalation of up to Forty Milligrams per Day of Oral Olanzapine in Acute Agitation', *Journal*

of *Clinical Psychopharmacology*, 23(4), pp. 342–348. doi: 10.1097/01.jcp.0000085406.08426.a8.

Ballon, J. dan Stroup, T. S. (2013) ‘Polypharmacy for schizophrenia’, *Current Opinion in Psychiatry*, 26(2), pp. 208–213. doi: 10.1097/YCO.0b013e32835d9efb.

Barnett, B. S. dkk. (2019) ‘Factors associated with long length of stay in an inpatient psychiatric unit in Lilongwe, Malawi’, *Social Psychiatry and Psychiatric Epidemiology*, 54(2), pp. 235–242. doi: 10.1007/s00127-018-1611-1.

Bauer, J. Ø. dkk. (2016) ‘Treatment of agitation in the acute psychiatric setting. An observational study of the effectiveness of intramuscular psychotropic medication’, *Nordic Journal of Psychiatry*, 70(8), pp. 599–605. doi: 10.1080/08039488.2016.1188982.

Belraka Khazhadhia, M.dkk. (2024) *Evaluasi Peresepan Obat Pasien Skizofrenia Lanjut Usia Di Unit Rawat Inap Rsud Dr. R. Soedjati Soemodiardjo Purwodadi Indonesia*, *Jurnal Medika Malahayati*.

Bereda, G. (2022) ‘Annals of Psychiatry and Mental Health Cite this article: Bereda G. Drug Therapy Problems in Schizophrenic Patients’, *Ann Psychiatry Ment Health*, 10(1), p. 1174.

Bereda, G. dan Bereda Gemechis (2021) ‘Prevalence of Drug Related Problems And Its Associated Factors Among Schizophrenic Patients In Psychiatric Ambulatory Clinic of Mettu Karl Referral Hospital, South Western, Ethiopia: A Prospective Cross Sectional Study’, *International Journal of Multidisciplinary Education and Research*, 6(3), pp. 40–45.

Blix, H. S. dkk. (2004) ‘The majority of hospitalised patients have drug-related problems: results from a prospective study in general hospitals’, *European Journal of Clinical Pharmacology*, 60(9), pp. 651–658. doi: 10.1007/s00228-004-0830-4.

Bole, C. dkk. (2023) ‘Potential Drug-Drug Interactions among Patients with Schizophrenia Spectrum Disorders: Prevalence, Association with Risk Factors, and Replicate Analysis in 2021’, *Medicina (Lithuania)*, 59(2). doi: 10.3390/medicina59020284.

Brunette, M. F. dkk. (2003) ‘Benzodiazepine Use and Abuse Among Patients With Severe Mental Illness and Co-occurring Substance Use Disorders’, *Psychiatric Services*, 54(10), pp. 1395–1401. doi: 10.1176/appi.ps.54.10.1395.

Brunton, L. L., Knollmann, B. C. dan Hilal-Dandan, R. (2018) *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 13th edn. New York: McGraw-Hill Education.

- Bugarski-Kirola, D. dkk. (1996) 'The efficacy of sulpiride in the treatment of negative forms of schizophrenia', *European Psychiatry*, 11, pp. 405s–406s. doi: 10.1016/0924-9338(96)89325-4.
- Burrer, A. dkk. (2024) 'Examining the impact of substance use on hospital length of stay in schizophrenia spectrum disorder: a retrospective analysis', *BMC Medicine*, 22(1), p. 233. doi: 10.1186/s12916-024-03447-3.
- Canuso, C. M. dan Pandina, G. (2007) 'Gender and schizophrenia.', *Psychopharmacology bulletin*, 40(4), pp. 178–90.
- Cao, B. dkk. (2018) 'Association between B vitamins and schizophrenia: A population-based case-control study', *Psychiatry Research*, 259, pp. 501–505. doi: 10.1016/j.psychres.2017.11.006.
- Caroff, S. N., Ungvari, G. S. dan Gazdag, G. (2024) 'Treatment of schizophrenia with catatonic symptoms: A narrative review', *Schizophrenia Research*, 263, pp. 265–274. doi: 10.1016/j.schres.2022.11.015.
- Chaumette, B. dkk. (2016) 'Stress et transition psychotique : revue de la littérature', *L'Encéphale*, 42(4), pp. 367–373. doi: 10.1016/j.encep.2015.10.001.
- Chen, E. dkk. (2021) 'Schizophrenia hospitalization in the US 2005–2014', *Medicine*, 100(15), p. e25206. doi: 10.1097/MD.00000000000025206.
- Chen, L. dkk. (2018) 'Risk factors in early and late onset schizophrenia', *Comprehensive Psychiatry*, 80, pp. 155–162. doi: 10.1016/j.comppsy.2017.09.009.
- Chong, H. Y. dkk. (2016) 'Global economic burden of schizophrenia: A systematic review', *Neuropsychiatric Disease and Treatment*. Dove Medical Press Ltd, pp. 357–373. doi: 10.2147/NDT.S96649.
- Correll, C. U. dkk. (2022) 'Mortality in People with Schizophrenia: A Systematic Review and Meta-Analysis of Relative Risk and Aggravating or Attenuating Factors', *WPA*, 21(2), pp. 248–271. doi: 10.1002/wps.20994.
- Crismon, M. L. , S. T. , dan B. P. F. (2023) *Schizophrenia, dalam: DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., dan Ellingrod, V. (Editor), Pharmacotherapy A Pathophysiologic Approach*. 12th edn. United States: Mc Graw Hill.
- Dewi, R., Hadriyati, A. dan Situngkir, E. N. (2025) 'Analisis Interaksi Obat Antidiabetik terhadap Clinical Outcome Pasien DM Tipe 2 di RS X Jambi', *Jurnal Akademika Baiturrahim Jambi*, 14(1), pp. 80–92. doi: 10.36565/jab.v14i1.898.
- Duppen, Z. dan Sienaert, P. (2020) *Time and Body*. Edited by C. Tewes and G. Stanghellini. Belgium: Cambridge University Press. doi: 10.1017/9781108776660.

- Etchecopar-Etchart, D. dkk. (2021) 'Comorbid Major Depressive Disorder in Schizophrenia: A Systematic Review and Meta-Analysis', *Schizophrenia Bulletin*, 47(2), pp. 298–308. doi: 10.1093/schbul/sbaa153.
- Falkenburg, J. dan Tracy, D. K. (2014) 'Sex and schizophrenia: a review of gender differences', *Psychosis*, 6(1), pp. 61–69. doi: 10.1080/17522439.2012.733405.
- Fatwa, N., Fikriah, I. dan Abdullah, Y. (2020) 'Gambaran Pola Pengobatan Antipsikotik pada Pasien Skizofrenia yang Mengalami Efek Samping Ekstrapiramidal di RSJD Atma Husada Mahakam Samarinda', *Jurnal Keperawatan Wiyata*, 1(1).
- Fernandez-Llimos, F. dkk. (2004) 'Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems', *Current Pharmaceutical Design*, 10(31), pp. 3947–3967. doi: 10.2174/1381612043382558.
- Firth, J. dkk. (2017) 'The effects of vitamin and mineral supplementation on symptoms of schizophrenia: a systematic review and meta-analysis', *Psychological Medicine*, 47(9), pp. 1515–1527. doi: 10.1017/S0033291717000022.
- Fitrikasari, A. dan Kartikasari, L. (2022) *Buku Ajar Skizofrenia*. Semarang: UNDIP Press Semarang.
- Ford, T. C. dkk. (2018) 'The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial', *Nutrients*, 10(12), p. 1860. doi: 10.3390/nu10121860.
- Fortuna, T. A., Rahmawati, F. dan Yasin, N. M. (2021) 'Hubungan Drug Related Problems (DRPs) dan Outcome Pengobatan Pada Pasien Tuberkulosis Dengan Diabetes Melitus', *JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice)*, 11(2), p. 122. doi: 10.22146/jmpf.62602.
- Fountoulakis, K. N. dkk. (2022) 'Gender, age at onset, and duration of being ill as predictors for the long-term course and outcome of schizophrenia: an international multicenter study', *CNS Spectrums*, 27(6), pp. 716–723. doi: 10.1017/S1092852921000742.
- Galling, B. dkk. (2018) 'Efficacy and safety of antidepressant augmentation of continued antipsychotic treatment in patients with schizophrenia', *Acta Psychiatrica Scandinavica*, 137(3), pp. 187–205. doi: 10.1111/acps.12854.
- Ganesan, S. dkk. (2008) 'Switching from other antipsychotics to once-daily extended release quetiapine fumarate in patients with schizophrenia', *Current Medical Research and Opinion*, 24(1), pp. 21–32. doi: 10.1185/030079908X253384.

- Garin, N. dkk. (2021) 'Mortality in People with Schizophrenia: A Systematic Review and Meta-Analysis of Relative Risk and Aggravating or Attenuating Factors', *Scientific Reports*, 11(1), p. 883. doi: 10.1038/s41598-020-80560-2.
- Gerolymos, C. dkk. (2024) 'Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia', *JAMA Network Open*, 7(3), p. e241527. doi: 10.1001/jamanetworkopen.2024.1527.
- Giordano, G. M. dkk. (2021) 'Gender Differences in Clinical and Psychosocial Features Among Persons With Schizophrenia: A Mini Review', *Frontiers in Psychiatry*, 12. doi: 10.3389/fpsy.2021.789179.
- Goga, L. Y. dan Marais, B. S. (2024) 'Schizophrenia and Schizoaffective Disorder: Length of Stay and Associated Factors', *South African Journal of Psychiatry*, 30. doi: 10.4102/sajpspsychiatry.v30i0.2237.
- Goldstone, L. W. dkk. (2015) 'Improving medication-related Outcomes for Patients with Psychiatric and Neurologic Disorders: Value of Psychiatric Pharmacists as Part of The Health Care Team', *Mental Health Clinician*, 5(1), pp. 1–28. doi: 10.9740/mhc.2015.01.001.
- González Pablos, E., Alonso Del Teso, F. dan Sanguino Andrés, R. (2006) 'Schizophrenia: Clinical Estate, Cognitive Deterioration and Chronicity | Esquizofrenia: Estado Clínico, Deterioro Cognitivo y Cronicidad', *Anales de Psiquiatria*, 22(1), pp. 17–22.
- Häfner, H. (2005) 'Gender Differences in Schizophrenia', *Psychoneuroendocrinology*, 28, pp. 17–54. doi: 10.1016/S0306-4530(02)00125-7.
- Hanief, N. dan Noor, D. N. (2021) 'Gambaran Penggunaan Obat Antipsikotik Pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Soeharto Heerdjan Periode Januari-Juni 2017', *Yarsi Journal of Pharmacology*, 2(1).
- Hjorthøj, C. dkk. (2017) 'Years of Potential Life Lost and Life Expectancy in Schizophrenia: A Systematic Review and Meta-analysis', *The Lancet Psychiatry*, 4(4), pp. 295–301. doi: 10.1016/S2215-0366(17)30078-0.
- Hui, C. dkk. (2015) 'The effect of paternal age on relapse in first-episode schizophrenia', *The Canadian Journal of Psychiatry / La Revue canadienne de psychiatrie*, 60(8), pp. 346–353.
- Hutauruk, S. dkk. (2024) 'Rational Use of Drugs in Patients with Schizophrenia at Inpatient Installation of Dr. Soeharto Heerdjan Hospital Jakarta, Indonesia', *JMMR (Jurnal Medicoeticolegal dan Manajemen Rumah Sakit)*, 13(1), pp. 43–58. doi: 10.18196/jmmr.v13i1.84.
- Igbinomwanhia, N. G., Olotu, S. O. dan James, B. O. (2017) 'Prevalence and Correlates of Antipsychotic Polypharmacy among Outpatients with Schizophrenia Attending a Tertiary Psychiatric Facility in Nigeria',

*Therapeutic Advances in Psychopharmacology*, 7(1), pp. 3–10. doi: 10.1177/2045125316672134.

Ikawati, Z. (2011) *Farmakoterapi Penyakit Sistem Saraf Pusat*. Yogyakarta: Bursa Ilmu.

Imania, W. (2022) *Cost Analysis Penggunaan Terapi Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Mutiara Sukma NTB Tahun 2020*. Bachelor's thesis. Universitas Mataram. Available at: <https://eprints.unram.ac.id/id/eprint/30520> (Accessed: 12 January 2026).

Indriani, A., Ardiningrum, W. dan Febrianti, Y. (2020a) 'Studi Penggunaan Kombinasi Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Yogyakarta', *Majalah Farmasetika*, 4. doi: 10.24198/mfarmasetika.v4i0.25882.

Institute of health Metrics dan Evaluation (IHME) (2019) *GBD Results - Global health data exchange (GHDx) Institute of health Metrics and Evaluation (IHME)*. Available at: <https://vizhub.healthdata.org/gbd-results> (Accessed: 14 February 2025).

Jayakumar, A. dkk. (2021) 'Critical Analysis of Drug Related Problems among Inpatients in the Psychiatry Department of a Tertiary Care Teaching Hospital: A Pharmacist Led Initiative', *Clinical Epidemiology and Global Health*, 11. doi: 10.1016/j.cegh.2021.100743.

Jeste, D. V. dan Maglione, J. E. (2013) 'Treating Older Adults with Schizophrenia: Challenges and Opportunities', *Schizophrenia Bulletin*, pp. 966–968. doi: 10.1093/schbul/sbt043.

Jusuf, H. dkk. (2024) 'Gambaran Penggunaan Obat Antipsikotik pada Pasien Skizofrenia di Puskesmas Kota Gorontalo', *Journal Syifa Sciences and Clinical Research*, 6(1). doi: 10.37311/jsscr.v6i1.23849.

Kahwenga, K. D., Mnukwa, L. dan Bronkhorst, E. (2025) 'The Treatment of Psychotic and Bipolar Disorders Within the South African Context: Perspectives of a Clinical Pharmacist', *Healthcare*, 13(12), p. 1456. doi: 10.3390/healthcare13121456.

Kammen, D. (1977) 'gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia', *American Journal of Psychiatry*, 134(2), pp. 138–143. doi: 10.1176/ajp.134.2.138.

Kaplan, H. I., Sadock, B. J. dan Grebb, J. A. (2010) *Sinopsis Psikiatri*. Jakarta: Binarupa Aksara.

Katzung, B. G. (2002) *Bagian II: Pengantar Farmakologi Otonom pada Farmakologi Dasar dan Klinik*. Jakarta: Penerbit Buku Kedokteran EGC.

Kay, S. R., Flszbeln, A. dan Qpjer, L. A. (1987) *The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia*. Available at: <https://academic.oup.com/schizophreniabulletin/article/13/2/261/1919795>.

Kementrian Kesehatan RI (2015) *Pedoman Nasional Pelayanan Kedokteran Jiwa*. Jakarta: Kemenkes RI.

Kementrian Kesehatan RI (2021) *Pedoman Pelayanan Kefarmasian pada Gangguan Jiwa*. Jakarta: Kementrian Kesehatan Republik Indonesia.

Kementerian Kesehatan Republik Indonesia (2023) *Survey Kesehatan Indonesia (SKI)*. Jakarta.

Kementrian Kesehatan RI (2015) *Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.02.02/MENKES/73/2015*. Jakarta: Kementrian Kesehatan RI.

Kennedy, D. (2016) 'B Vitamins and the Brain: Mechanisms, Dose and Efficacy—A Review', *Nutrients*, 8(2), p. 68. doi: 10.3390/nu8020068.

Kitagawa, K. dkk. (2024) 'Changes in Psychopharmacotherapy for Patients with Schizophrenia in a Psychiatric Institution in Japan: A 12-year Prescription Survey Pre- and Post-introduction of Clozapine', *Asian Journal of Psychiatry*, 96. doi: 10.1016/j.ajp.2024.104047.

Lähteenpuo, M. dan Tiihonen, J. (2021) 'Antipsychotic Polypharmacy for the Management of Schizophrenia: Evidence and Recommendations', *Drugs*, 81(11), pp. 1273–1284. doi: 10.1007/s40265-021-01556-4.

Lexicomp (2026) *Lexicomp® drug interaction UpToDate inc*. Available at: <https://www.uptodate.com/content-not-available#di-druglist> (Accessed: 5 January 2026).

Liu, N. H. dkk. (2017) 'Excess Mortality in Persons with Severe Mental Disorders: a Multilevel Intervention Framework and Priorities for Clinical Practice, Policy and Research Agendas', *World Psychiatry*, 16(1), pp. 30–40. doi: 10.1002/wps.20384.

Liu, X.-F. dkk. (2023) 'Affected cortico-striatal-cerebellar network in schizophrenia with catatonia revealed by magnetic resonance imaging: indications for electroconvulsive therapy and repetitive transcranial magnetic stimulation', *Psychoradiology*, 3. doi: 10.1093/psyrad/kkad019.

Lwanga, S. K. dan Lemeshow, S. (1991) *Sample Size Determination Health Studies: A Practical Manual*. Geneva: World Health Organization.

MacFadden, W. dkk. (2010) 'Risperidone long-acting therapy in stable patients with recently diagnosed schizophrenia', *International Clinical Psychopharmacology*, 25(2), pp. 75–82. doi: 10.1097/YIC.0b013e3283347cbf.

- Mamo M dan Azzopardi LM (2016) 'Pharmacist Intervention in Patient Monitoring in a Psychiatric Setting', *Journal of Euromed Pharmacy*, 6, pp. 12–15.
- Marder and Cannon (2025) *Schizophrenia in Adults: Clinical Features, Assessment, and Diagnosis, UpToDate*. Available at: <https://www.uptodate.com/contents/schizophrenia-in-adults-clinical-features-assessment-and-diagnosis> (Accessed: 18 March 2025).
- Miron, A. A. dkk. (2023) 'Benzodiazepines and Mood Stabilizers in Schizophrenia Patients Treated with Oral versus Long-Acting Injectable Antipsychotics—An Observational Study', *Brain Sciences*, 13(2), p. 173. doi: 10.3390/brainsci13020173.
- Miyamoto, S. dkk. (2012) 'Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents', *Molecular Psychiatry*, 17(12), pp. 1206–1227. doi: 10.1038/mp.2012.47.
- Moniem, I. dan Kafetzopoulos, V. (2025) 'Sex differences in schizophrenia: symptomatology, treatment efficacy and adverse effects', *Frontiers in Psychiatry*, 16. doi: 10.3389/fpsy.2025.1594334.
- Montoya, A. dkk. (2011a) 'Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a naturalistic sample of 278 patients with acute psychosis and agitation in a psychiatric emergency room', *Health and Quality of Life Outcomes*, 9(1), p. 18. doi: 10.1186/1477-7525-9-18.
- Montoya, A. dkk. (2011b) 'Validation of the Excited Component of the Positive and Negative Syndrome Scale (PANSS-EC) in a Naturalistic Sample of 278 Patients with Acute Psychosis and Agitation in a [psychiatric Emergency Room]', *Health and Quality of Life Outcomes*, 9. doi: 10.1186/1477-7525-9-18.
- Mosolov, S. N. (2020) 'Diagnosis and treatment depression in schizophrenia', *Consortium PSYCHIATRICUM*, 1(2), pp. 29–42. doi: 10.17650/2712-7672-2020-1-2-29-42.
- Mulyani, S. (2024) 'The Impact of Socio-demographic Factors on the Recovery Potential of Schizophrenia Patients Post Hospitalization', *Journal of Epidemiology and Public Health*, 9(3), pp. 318–326. doi: 10.26911/jepublichealth.2024.09.03.05.
- Nabilah, T., Dewi, N. M. A. R. dan Aini, S. R. (2023) 'Evaluasi kesesuaian persepahan obat terhadap formularium nasional di Rumah Sakit Umum Daerah Sumbawa tahun 2021', *Sasambo Journal of Pharmacy*, 4(1), pp. 14–18. doi: 10.29303/sjp.v4i1.204.

- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (2017) *Anticholinergic Agents in LiverTox: Clinical and Research Information on Drug-Induced Liver Injury*. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK548287/> (Accessed: 30 January 2026).
- Naz, F. dkk. (2022) 'Bromocriptine therapy: Review of mechanism of action, safety and tolerability', *Clinical and Experimental Pharmacology and Physiology*, 49(8), pp. 903–922. doi: 10.1111/1440-1681.13678.
- Ningsih, T. S. dkk. (2023) 'FAKUMI MEDICAL JOURNAL', *Fakumi Medical Journal: Jurnal Mahasiswa Kedokteran*, 3. Available at: <https://fmj.fk.umi.ac.id/index.php/fmj> (Accessed: 10 January 2026).
- Nurrohmah, A. dkk. (2024) 'Profil PANSS-EC dan Diagnosis Pasien Terapi Kejang Listrik', *Journal of Language and Health*, 5(3), pp. 1541–1544.
- Obermeier, M. dkk. (2011) 'Is The PANSS Used Correctly? A Systematic Review', *BMC Psychiatry*, 11. doi: 10.1186/1471-244X-11-113.
- Oktasari, S. R. (2024) *Hubungan Antara Kejadian Drug Related Problems (DRP) dan Luaran Klinis Pada Pasien Skizofrenia*. Tesis S2. Universitas Gadjah Mada.
- Park, S.-C. dkk. (2020) 'Relationship between body mass index and extrapyramidal symptoms in asian patients with schizophrenia: The research on asian psychotropic prescription patterns for antipsychotics (reap-ap)', *Psychiatry Danubina*, 32(2), pp. 176–186. doi: 10.24869/psyd.2020.176.
- Patel, K. R. dkk. (2014) 'Schizophrenia: Overview and Treatment Options', *P&T*, 39(9), pp. 638–644.
- Patrichi, B. dkk. (2021) 'Antipsychotic polypharmacy in adult patients diagnosed with schizophrenia: A retrospective study', *Experimental and Therapeutic Medicine*, 22(5), p. 1225. doi: 10.3892/etm.2021.10659.
- Pereira, S. R. dan Albert, M. (2017) 'Anticholinergic discontinuation for antipsychotic-induced extra-pyramidal symptoms', *Cochrane Database of Systematic Reviews*. doi: 10.1002/14651858.CD012525.
- Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia (PDSKJI) (2011) *Konsensus Penatalaksanaan Gangguan Skizofrenia*. Perhimpunan Dokter Spesialis Kedokteran Jiwa Indonesia (PDSKJI).
- Petrovic, A. D. dkk. (2025) 'Safety Profile of Antipsychotics as Predictors of the Quality of Life in Patients with Schizophrenia—An Inpatient Welfare Institution-Based Cross-Sectional Study', *Pharmaceuticals*, 18(6), p. 777. doi: 10.3390/ph18060777.

- Pharmaceutical Care Network Europe Association (PCNE) (2019) *Classification for Drug Related Problems v9.00*. Available at: [https://www.pcne.org/upload/files/334\\_PCNE\\_classification\\_V9-0.pdf](https://www.pcne.org/upload/files/334_PCNE_classification_V9-0.pdf) (Accessed: 19 February 2025).
- Pratts, M. dkk. (2014) 'A Single-dose, Randomized, Double-blind, Placebo-controlled Trial of Sublingual Asenapine for Acute Agitation', *Acta Psychiatrica Scandinavica*, 130(1), pp. 61–68. doi: 10.1111/acps.12262.
- Pringsheim, T. dkk. (2018) 'The Assessment and Treatment of Antipsychotic-Induced Akathisia', *The Canadian Journal of Psychiatry*, 63(11), pp. 719–729. doi: 10.1177/0706743718760288.
- Puranen, A. dkk. (2023) 'Real-world effectiveness of mood stabilizer use in schizophrenia', *Acta Psychiatrica Scandinavica*, 147(3), pp. 257–266. doi: 10.1111/acps.13498.
- Purwandityo, A. G. dkk. (2018) 'The Influence of Antipsychotic to Decrease the Score of The Positive and Negative Syndrome Scale-Excited Component', *Indonesian Journal of Clinical Pharmacy*, 7(1), pp. 19–29. doi: 10.15416/ijcp.2018.7.1.19.
- Purwohadi, S. (2021) *Evaluasi Pola Pengobatan pada Pasien Skizofrenia Rawat Inap di Rumah Sakit Jiwa*. UII. Available at: Evaluasi pola pengobatan pada pasien skizofrenia rawat inap di Rumah Sakit Jiwa (Accessed: 27 January 2026).
- Putri, T. H. dan Agustia, Y. (2021) 'Faktor Karakteristik dalam Kejadian Kekambuhan pada Pasien Skizofrenia Characteristic Factors Affecting Relapse of Schizophrenia Patients', *Jurnal Kesehatan*, 13(1). Available at: <http://ejurnal.poltekkes-tjk.ac.id/index.php/JK>.
- Ramani, A. dkk. (2024) 'What Family Determinants Are Associated With the Duration of Hallucinatory Disorders in the City of Surabaya, East Java, Indonesia?', *Malaysian Journal of Medicine and Health Sciences*, 20(SUPP9), pp. 22–26. doi: 10.47836/mjmhs20.s9.4.
- Ram dini, D. A. dkk. (2018) 'Potensi Interaksi Obat pada Pasien Skizofrenia di Salah Satu Rumah Sakit Jiwa di Provinsi Jawa Barat', *Indonesian Journal of Clinical Pharmacy*, 7(4), p. 280. doi: 10.15416/ijcp.2018.7.4.280.
- Ran, M.-S. dkk. (2015) 'Gender differences in outcomes in people with schizophrenia in rural China: 14-year follow-up study', *British Journal of Psychiatry*, 206(4), pp. 283–288. doi: 10.1192/bjp.bp.113.139733.
- Ratnasari, I. D. (2018) 'Analisis Drug Related Problem Penggunaan Antipsikotik pada Penderita Schizophrenia Dewasa di Rumah Sakit Surabaya', *Jurnal Ilmiah Mahasiswa Universitas Surabaya*, 7(1), pp. 721–735.
- Resmiati, W., Arozal, W. dan Laksmiawati, D. R. (2023) *Identifikasi Drug Related Problems pada Pasien Skizofrenia dengan Komorbid di RSJ dr. H Marzoeki*

*Mahdi Bogor Identification of Drug-Related Problems in Schizophrenic Patients with Comorbidities at RSJ dr. H Marzoeki Mahdi Bogor, Pharmaceutical Journal of Indonesia).*

Reynolds, E. (2006) 'Vitamin B12, folic acid, and the nervous system', *The Lancet Neurology*, 5(11), pp. 949–960. doi: 10.1016/S1474-4422(06)70598-1.

Riedel, M. dkk. (2008) 'Quetiapine XR – A New Retard Formulation in the Treatment of Schizophrenia', *Pharmacopsychiatry*, pp. 70–75.

Rissa, M. M. dan Darmawan, E. (2021) 'Nilai PANSS–EC Dan GAF Pada Pasien Gangguan Mental Psikotik Yang Diterapi Atypical-Atypical Dan Atypical-Typical Di Rumah Sakit Jiwa Grhasia Yogyakarta', *Pharmaceutical Journal of Islamic Pharmacy*, 5(1), p. 15. doi: 10.21111/pharmasipha.v5i1.3941.

Roy, D. A. dkk. (2020) 'Drug-related Problems among Chronic Kidney Disease Patients: A Clinical Pharmacist Led Study', *International Journal of Pharmaceutical Research*, 12(4), pp. 79–84. doi: 10.31838/ijpr/2020.12.04.017.

Rummel, C., Kissling, W. dan Leucht, S. (2005) 'Antidepressants as add-on treatment to antipsychotics for people with schizophrenia and pronounced negative symptoms: A systematic review of randomized trials', *Schizophrenia Research*, 80(1), pp. 85–97. doi: 10.1016/j.schres.2005.07.035.

San, L., Rubio, G. dan Bernardo-Fernandez, I. (2011) 'Immediate Clinical Assessment of Medical Intervention in Schizophrenic Patients Admitted to an Acute-care Psychiatric Unit: A Retrospective, Naturalistic and Multicenter Study', *International Journal of Psychiatry in Clinical Practice*, 15(3), pp. 196–203. doi: 10.3109/13651501.2011.583665.

Saputri, I. S. P. A. (2023) 'Kajian Penggunaan Antipsikotik pada Pasien Skizofrenia di Instalasi Rawat Inap', *Enfermeria Ciencia*, 1(2), pp. 122–130. doi: 10.56586/ec.v1i2.10.

Satria, M. A., Andrajati, R. dan Supardi, S. (2022) 'The Translation Process of Pharmaceutical Care Network Europe v9.00 to Bahasa Indonesia: An Instrument to Detect Drug-Related Problem', *Malaysian Journal of Medical Sciences*, 29(3), pp. 133–144. doi: 10.21315/mjms2022.29.3.13.

Shams-Alizadeh, Narges dkk. (2018) 'Effect of Vitamin B6 Versus Propranolol on Antipsychotic-Induced Akathisia: A pilot Comparative Double-blind Study.', *Iranian journal of pharmaceutical research : IJPR*, 17(Suppl), pp. 130–135.

Shirzad-Yazdi, N. dkk. (2024) 'Drug-related problems among pediatric intensive care units: prevalence, risk factors, and clinical pharmacists' interventions', *BMC Pediatrics*, 24(1). doi: 10.1186/s12887-024-05185-0.

- Sholihah, R., Anggraeni, N. dan Purwanta (2023) 'Unraveling the relationship between the DRPs with PANNS and extrapyramidal symptoms in schizophrenia: Implications for antipsychotic therapy ', *Jurnal Aisyah: Jurnal Ilmu Kesehatan*, 10(1), pp. 414–424.
- Siddiqua, A., Abdullah, R. K. dan Kareem, N. A. (2019) 'Impact of Clinical Pharmacist Intervention towards Polypharmacy in Elderly population-A Systematic Study', *Research Journal of Pharmacy and Technology*, 12(6), p. 2621. doi: 10.5958/0974-360x.2019.00439.6.
- Sim, F. dkk. (2015) 'Re-examining the role of benzodiazepines in the treatment of schizophrenia: A systematic review', *Journal of Psychopharmacology*, 29(2), pp. 212–223. doi: 10.1177/0269881114541013.
- Skinner, J. P., Shinn, A. K. dan Moran, L. V (2025) 'Risk Factors for Late-Onset Psychosis: A Case-Control Study', *Schizophrenia Bulletin*, 51(5), pp. 1417–1427. doi: 10.1093/schbul/sbae164.
- Skoretz, P. dan Tang, C. (2016) 'Stimulants for impulsive violence in schizophrenia spectrum disordered women: a case series and brief review', *CNS Spectrums*, 21(6), pp. 445–449. doi: 10.1017/S1092852915000796.
- Soubolsky, A. dan Halpape, K. (2022) 'The Time is Now for Mental Health Care: Evaluating the Impact of a Clinical Pharmacist on an Acute Mental Health Unit', *Canadian Journal of Hospital Pharmacy*, 75(4), pp. 317–325. doi: 10.4212/cjhp.3210.
- Stašević, M. dkk. (2020) 'Patterns of drug prescribing in inpatients with first episode of schizophrenia spectrum disorder: The role of guidelines<sup>[P]</sup><sub>SEP</sub>', *Int. Journal of Clinical Pharmacology and Therapeutics*, 58(07), pp. 387–394. doi: 10.5414/CP203704.
- Stimmel, G. L. (1996) 'Benzodiazepines in schizophrenia.', *Pharmacotherapy*, 16(6 Pt 2), pp. 148S-151S; discussion 166S-168S.
- Stough, C. dkk. (2014) 'Reducing occupational stress with a B-vitamin focussed intervention: a randomized clinical trial: study protocol', *Nutrition Journal*, 13(1), p. 122. doi: 10.1186/1475-2891-13-122.
- Strutton, D. R., Gutierrez, B. dan Blanchette, C. M. . (2008) 'Influence of medication treatment patterns on resource use for patients hospitalized for schizophrenia', *American Journal of Health-System Pharmacy*, 65(1), pp. 42–48. doi: 10.2146/ajhp060635.
- Sulejmanpasic, G. dkk. (2023) 'The Correlation of Positive and Negative Symptoms (PANSS Scores) in Patients with Schizophrenia According to Gender', *Medical Archives*, 77(2), pp. 123–126. doi: 10.5455/medarh.2023.77.123-126.

- Szarmach, J. *dkk.* (2017) 'Benzodiazepines as adjunctive therapy in treatment refractory symptoms of schizophrenia.', *Psychiatria Danubina*, 29(Suppl 3), pp. 349–352.
- Tan, H. Tjay. (2007) *Obat-obat penting: khasiat, penggunaan dan efek-efek sampingnya*. Elex Media Komputindo.
- Tandon, R. *dkk.* (2020) 'The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey', *Annals of General Psychiatry*, 19(1), p. 42. doi: 10.1186/s12991-020-00292-5.
- Tasaka, Y. *dkk.* (2018) 'Potential Drug-related Problems Detected by Routine Pharmaceutical Interventions: Safety and Economic Contributions Made by Hospital Pharmacists in Japan', *Journal of Pharmaceutical Health Care and Sciences*, 4(1), p. 33. doi: 10.1186/s40780-018-0125-z.
- Tauscher-Wisniewski, S. *dkk.* (2002) 'Quetiapine: An Effective Antipsychotic in First-Episode Schizophrenia Despite Only Transiently High Dopamine-2 Receptor Blockade', *The Journal of Clinical Psychiatry*, 63(11), pp. 992–997. doi: 10.4088/JCP.v63n1106.
- Temtem, G. *dkk.* (2023) 'Drug Therapy Problems in Patients with Schizophrenia: A Cross-Sectional Study', *Clinical Medicine Insights: Psychiatry*, 14. doi: 10.1177/11795573231222147.
- Tesfaye, S. *dkk.* (2016) 'Prevalence of Antipsychotic Polypharmacy and Associated Factors among Outpatients with Schizophrenia Attending Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia', *Psychiatry Journal*, 2016, pp. 1–6. doi: 10.1155/2016/6191074.
- Tor, P.-C. *dkk.* (2011) 'Adjunctive benzodiazepine treatment of hospitalized schizophrenia patients in Asia from 2001 to 2008', *The International Journal of Neuropsychopharmacology*, 14(06), pp. 735–745. doi: 10.1017/S146114571000163X.
- Toto, S. *dkk.* (2019) 'Psychopharmacological Treatment of Schizophrenia Over Time in 30 908 Inpatients: Data From the AMSP Study', *International Journal of Neuropsychopharmacology*, 22(9), pp. 560–573. doi: 10.1093/ijnp/pyz037.
- Tseng, P.-T. *dkk.* (2016) 'Significant Effect of Valproate Augmentation Therapy in Patients With Schizophrenia', *Medicine*, 95(4), p. e2475. doi: 10.1097/MD.0000000000002475.
- Utami, V. W. *dkk.* (2022) 'Pharmaceutical Journal of Indonesia Profil Drug Related Problems (DRPs) pada Pasien Skizofrenia di Instalasi Rawat Inap Rumah Sakit Jiwa Mutiara Sukma Provinsi NTB Tahun 2020', *Pharmaceutical Journal of Indonesia*, 8(1), pp. 87–94. Available at: <http://.pji.ub.ac.id>.

- Ventura, F. *dkk.* (2021) 'Schizophrenia and substance use disorder: a retrospective study of a dual diagnosis patients cohort', *Psychiatry*, 18(3), pp. 182–189. doi: 10.5603/PSYCH.2021.0021.
- Viktil, K. K. *dkk.* (2007) 'Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems', *British Journal of Clinical Pharmacology*, 63(2), pp. 187–195. doi: 10.1111/j.1365-2125.2006.02744.x.
- Vochoskova, K. *dkk.* (2024) 'Trajectories of Daily Antipsychotic Use and Weight Gain in People Hospitalized for The First Episode of Psychosis', *European Psychiatry*, 67(1), p. e59. doi: 10.1192/j.eurpsy.2024.1761.
- Wahyu Syah Putra, D. E. *dkk.* (2023) 'Ketepatan Penggunaan Antipsikotik pada Pasien Skizofrenia di Rumah Sakit Jiwa Dr. Radjiman Wediodiningrat', *Indonesian Journal of Pharmaceutical Education*, 3(3). doi: 10.37311/ijpe.v3i3.23235.
- Walker, E., Mittal, V. dan Tessner, K. (2008) 'Stress and the Hypothalamic Pituitary Adrenal Axis in the Developmental Course of Schizophrenia', *Annual Review of Clinical Psychology*, 4(1), pp. 189–216. doi: 10.1146/annurev.clinpsy.4.022007.141248.
- Walpore, R. E. *dkk.* (2011) *Probability and Statistics for Engineers and Scientists*. 9th edn. US: Pearson Education Inc.
- Wang, J. dan Sampson, S. (2014) 'Sulpiride versus placebo for schizophrenia', *Cochrane Database of Systematic Reviews*, 2014(4). doi: 10.1002/14651858.CD007811.pub2.
- Wang, Y. *dkk.* (2016) 'Valproate for schizophrenia', *Cochrane Database of Systematic Reviews*, 2016(11). doi: 10.1002/14651858.CD004028.pub4.
- Wardhani, F. A., Ikawati, Z. dan Yasin, N. M. (2023) 'Hubungan antara Kejadian Drug Related Problems (DRPs) dengan Outcome Klinis pada Pasien Stroke Iskemik', *Majalah Farmaseutik*, 19(1). doi: 10.22146/farmaseutik.v19i1.74413.
- Weng, J. *dkk.* (2019) 'Study on risk factors of extrapyramidal symptoms induced by antipsychotics and its correlation with symptoms of schizophrenia', *General Psychiatry*, 32(1), p. e100026. doi: 10.1136/gpsych-2018-100026.
- Whalen, Karen., Finkel, Richard. dan Panavelil, T. A. . (2015) *Pharmacology*. 6th edn. Wolters Kluwer.
- Wheeler, A. *dkk.* (2007) 'Sedative-hypnotic treatment in an acute psychiatric setting: comparison with best practice guidance', *Pharmacy World & Science*, 29(6), pp. 603–610. doi: 10.1007/s11096-007-9096-0.
- Wijiani Yanti, N. K. dan i Andayani, D. (2021) 'Evaluasi Tepat Pasien, Tepat Obat, Dan Tepat Dosis Penggunaan Antipsikotik Pasien Skizofrenia Di Rumah

Sakit Jiwa Provinsi NTB', *Jurnal Insan Farmasi Indonesia*, 4(1), pp. 111–120. doi: 10.36387/jifi.v4i1.658.

Wilianto, R. Y. dan Yulistiani (2019) 'Side Effects of Antipsychotics on Schizophrenia Patients : A Literature Review', *Pharmaceutical Journal of Indonesia*, 2019(2), pp. 35–44. Available at: <http://pji.ub.ac.id>.

Włodarczyk, A. dkk. (2017) 'Benzodiazepines in combination with antipsychotic drugs for schizophrenia: GABA-ergic targeted therapy.', *Psychiatria Danubina*, 29(Suppl 3), pp. 345–348.

World Health Organizaion (WHO) (2025) *ICD-11 for Mortality and Morbidity Statistics*. Available at: <https://icd.who.int/browse/2025-01/mms/en#1683919430> (Accessed: 17 March 2025).

World Health Organization (2013) *The Use of The WHO-UMC System for Standardised Case Causality Assessment*. Available at: <https://www.who.int/publications/m/item/WHO-causality-assessment> (Accessed: 10 May 2025).

World Health Organization (WHO) (2016) *International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD-10): Version 2016*, World Health Organization. Available at: <https://icd.who.int/browse10/2016/en#/G25.5> (Accessed: 13 February 2026).

Yulianti, Y. (2015) 'Cetak Biru Pelayanan Pasien di Rumah Sakit Jiwa Provinsi Jawa Barat Tahun 2014', *Jurnal Administrasi Rumah Sakit Indonesia*, 1(2). doi: 10.7454/arsi.v1i2.2174.

Yulianty, M. D., Cahaya, N. dan Srikartika, V. M. (2017) 'Studi Penggunaan Antipsikotik dan Efek Samping pada Pasien Skizofrenia di Rumah Sakit Jiwa Sambang Lihum Kalimantan Selatan', *JSFK : Jurnal Sains Farmasi dan Klinis*, 3(2), pp. 153–164.

Zakiyah, N. (2024) *Profil persepsian antipsikotik pada pasien rawat jalan di poliklinik jiwa Rumah Sakit Islam Jakarta Cempaka Putih periode Oktober–Desember 2023 (Diploma thesis)*. Politeknik Kesehatan Kemenkes Jakarta II.

Zeller, S. dkk. (2017) 'Response to Inhaled Loxapine in Patients with Schizophrenia or Bipolar I Disorder: PANSS-EC Responder Analyses', *BJPsych Open*, 3(6), pp. 285–290. doi: 10.1192/bjpo.bp.117.005363.

Zhand, N. dkk. (2024) 'Adjunctive methylphenidate extended release in patients with schizophrenia: Protocol of a single-centre fixed dose cross-over open-label trial to improve functional and cognitive outcomes', *Contemporary Clinical Trials Communications*, 41, p. 101337. doi: 10.1016/j.conctc.2024.101337.

Zhang, M.-D. dan Mao, Y.-M. (2015) 'Augmentation with antidepressants in schizophrenia treatment: benefit or risk', *Neuropsychiatric Disease and Treatment*, p. 701. doi: 10.2147/NDT.S62266.

Zulkifli, A. dan Febriyana, N. (2017) 'Efek Penggunaan Obat Antikolinergik Pada Pasien Skizofrenia', *Jurnal Psikiatri Surabaya*, 6(2), p. 58. doi: 10.20473/jps.v6i2.19428.